Chemical Property of Plegomazin
Chemical Property:
- Appearance/Colour:creamy white crystalline powder
- Melting Point:192-196 °C
- Boiling Point:450.1 °C at 760 mmHg
- Flash Point:226 °C
- PSA：31.78000
- Density:1.077 g/cm3 (15 C)
- LogP:5.76140
- Storage Temp.:-20°C Freezer
- Solubility.:Very soluble in water, freely soluble in ethanol (96 per cent). It decomposes on exposure to air and light.
- Water Solubility.:>=10 g/100 mL at 24 ºC
- Hydrogen Bond Donor Count:1
- Hydrogen Bond Acceptor Count:4
- Rotatable Bond Count:4
- Exact Mass:354.0724252
- Heavy Atom Count:22
- Complexity:339
- Purity/Quality:
-
99%, *data from raw suppliers
Chlorpromazine Hydrochloride *data from reagent suppliers
Safty Information:
- Pictogram(s):
T+
- Hazard Codes:T+,T,F
- Statements:
25-26-39/23/24/25-23/24/25-11
- Safety Statements:
28-36/37-45-16
- MSDS Files:
-
SDS file from LookChem
Total 1 MSDS from other Authors
Useful:
- Canonical SMILES:[H+].CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl.[Cl-]
-
Uses
Chlorpromazine hydrochloride is used in the treatment of schizophrenia; anti-emetic; as an antipsychotic in pills, injections, and suppositories; to relieve nausea and
vomiting associated with malignant diseases. In veterinary medicine, it is used as an anti-emetic, tranquilizer and sedative. It has slight
antihistaminic and anti adrenaline actions. It is a peripheral vasodilator and adepressant that blocks dopamine receptors in the central
nervous system. Antiemetic;Dopamine antagonist Used as an Antiemetic, Antipsychotic
-
Therapeutic Function
Tranquilizer
-
Clinical Use
#N/A
-
Drug interactions
Potentially hazardous interactions with other drugs
Anaesthetics: enhanced hypotensive effect.
Analgesics: increased risk of convulsions with
tramadol; enhanced hypotensive and sedative
effects with opioids; increased risk of ventricular
arrhythmias with methadone.
Anti-arrhythmics: increased risk of ventricular
arrhythmias with anti-arrhythmics that prolong
the QT interval and disopyramide; avoid with
amiodarone and dronedarone.
Antibacterials: increased risk of ventricular
arrhythmias with delamanid, moxifloxacin and
telithromycin - avoid with moxifloxacin.
Antidepressants: increased level of tricyclics,
possibly increased risk of ventricular arrhythmias
and antimuscarinic side effects; increased risk
of ventricular arrhythmias with citalopram and
escitalopram - avoid; increased risk of convulsions
with vortioxetine.
Anticonvulsants: antagonises anticonvulsant effect;
concentration of fosphenytoin and phenytoin
possibly increased or decreased; concentration of
both drugs reduced with phenobarbital.
Antimalarials: avoid with artemether/lumefantrine
and piperaquine with artenimol.
Antipsychotics: increased risk of ventricular
arrhythmias with droperidol and pimozide - avoid;
concentration of haloperidol possibly increased;
possible increased risk of ventricular arrhythmias
with risperidone.
Antivirals: concentration possibly increased with
ritonavir; increased risk of ventricular arrhythmias
with saquinavir - avoid.
Anxiolytics and hypnotics: increased sedative effects.
Atomoxetine: increased risk of ventricular
arrhythmias.Beta-blockers: enhanced hypotensive effect;
concentration of both drugs may increase
with propranolol; increased risk of ventricular
arrhythmias with sotalol.
Cytotoxics: increased risk of ventricular arrhythmias
with vandetanib - avoid; increased risk of ventricular
arrhythmias with arsenic trioxide.
Diuretics: enhanced hypotensive effect.
Lithium: increased risk of extrapyramidal side effects
and possibly neurotoxicity.
Pentamidine: increased risk of ventricular
arrhythmias.
Ulcer-healing drugs: effects enhanced by cimetidine.
